# CancerGenomics.AI - Business Plan & Technical Architecture

## Executive Summary

**CancerGenomics.AI** is a self-service SaaS platform that democratizes cancer genomics analysis for small-to-medium research labs. By leveraging AI agents and ultra-budget LLMs (DeepSeek, Qwen, Kimi K2), we can offer professional-grade genomics analysis at **1/100th the cost** of traditional services.

**Market Opportunity**: $28B genomics market by 2026, with 10,000+ cancer research labs globally lacking bioinformatics capacity.

**Business Model**: Freemium SaaS with tiered pricing ($99-$999/month)

**Competitive Advantage**:
- 98% lower COGS than competitors
- Instant results (2 min vs weeks)
- No bioinformatics expertise required
- Publication-ready outputs

**Revenue Projections**:
- Year 1: $358K ARR
- Year 2: $1.5M ARR
- Year 3: $5M ARR

---

## Market Analysis

### Target Market

**Primary**: Small-to-medium cancer research labs (universities, hospitals, biotech startups)
- 10,000+ labs globally
- Annual genomics budget: $50K-500K
- Pain points: No dedicated bioinformatics team, long turnaround times, high costs

**Secondary**: Clinical oncologists, pharmaceutical companies, CROs

### Market Size

- **TAM** (Total Addressable Market): $28B genomics market
- **SAM** (Serviceable Addressable Market): $3B (cancer genomics analysis services)
- **SOM** (Serviceable Obtainable Market): $150M (self-service cancer genomics)

### Competition

| Competitor | Price/Sample | Turnaround | Self-Service | Our Advantage |
|------------|--------------|------------|--------------|---------------|
| **Tempus** | $1,500-3,000 | 2-3 weeks | ❌ | 300x cheaper, instant |
| **Foundation Medicine** | $3,000-5,000 | 2-4 weeks | ❌ | 600x cheaper, instant |
| **DNAnexus** | $50-200 | Hours-Days | ⚠️ (complex) | 10x cheaper, easier |
| **Local Bioinformatician** | $80K-150K/year | Varies | ❌ | No hiring needed |
| **CancerGenomics.AI** | $1-5 | 2 minutes | ✅ | **Our solution** |

---

## Product Overview

### Core Features (MVP)

**1. Mutation Analysis**
- Upload CSV/VCF files (drag-and-drop)
- Automatic driver gene identification (TP53, KRAS, PIK3CA, BRAF, etc.)
- Mutation type classification (missense, nonsense, frameshift, etc.)
- Variant allele frequency (VAF) analysis

**2. Pathway Enrichment**
- 10 major cancer pathways (RAS/RAF, PI3K/AKT, TP53, DNA repair, etc.)
- Statistical significance testing
- Pathway visualization (interactive diagrams)

**3. Tumor Mutational Burden (TMB)**
- TMB calculation per sample
- Immunotherapy eligibility prediction
- Comparison to TCGA benchmarks

**4. Actionable Mutations**
- FDA-approved targeted therapy recommendations
- Clinical trial matching
- Drug-gene interaction database

**5. Reporting**
- Publication-ready PDF reports
- Interactive visualizations (Plotly charts)
- Downloadable results (CSV, Excel, JSON)
- Code generation (Python) for reproducibility

### User Interface

```
┌─────────────────────────────────────────────┐
│  CancerGenomics.AI                    Login │
├─────────────────────────────────────────────┤
│                                             │
│  Upload Your Mutation Data                  │
│  ┌─────────────────────────────────────┐   │
│  │  Drag & Drop CSV/VCF                │   │
│  │  or click to browse                 │   │
│  │                                     │   │
│  │  📁  mutations.csv                  │   │
│  └─────────────────────────────────────┘   │
│                                             │
│  Analysis Options:                          │
│  ☑ Driver Gene Identification              │
│  ☑ Pathway Enrichment                      │
│  ☑ TMB Calculation                         │
│  ☑ Actionable Mutations                    │
│                                             │
│  [Analyze Now] ────────────────────────    │
│                                             │
│  Previous Analyses:                         │
│  • TCGA_BRCA_cohort.csv - 2024-12-21       │
│  • Patient_001_WES.vcf - 2024-12-20        │
│                                             │
└─────────────────────────────────────────────┘
```

---

## Technical Architecture

### System Architecture

```
┌──────────────┐
│   Frontend   │  Next.js + React + Tailwind
│   (Vercel)   │  - File upload
└──────┬───────┘  - Dashboard
       │          - Reports viewer
       │
       ↓
┌──────────────┐
│  API Gateway │  FastAPI + Python
│   (Railway)  │  - Authentication (JWT)
└──────┬───────┘  - Rate limiting
       │          - Payment processing (Stripe)
       │
       ↓
┌──────────────┐
│   Analysis   │  ai-data-science-team library
│    Engine    │  - GenomicsAnalysisAgent
└──────┬───────┘  - OpenRouter integration
       │          - Result caching (Redis)
       │
       ↓
┌──────────────┐
│   OpenRouter │  DeepSeek Chat ($0.14/M tokens)
│   API        │  Qwen 2.5 ($0.35/M tokens)
└──────┬───────┘  Kimi K2 ($0.20/M tokens)
       │
       ↓
┌──────────────┐
│   Database   │  PostgreSQL (Supabase)
│   (Supabase) │  - User data
└──────────────┘  - Analysis history
                  - Reports (PDF storage)
```

### Tech Stack

**Frontend**:
- Next.js 14 (App Router)
- React 18
- Tailwind CSS
- Shadcn UI components
- Recharts for visualizations

**Backend**:
- FastAPI (Python 3.11+)
- ai-data-science-team library (already built!)
- OpenRouter integration (ultra-budget models)
- Celery for async tasks
- Redis for caching

**Database**:
- PostgreSQL (Supabase)
- Redis (Upstash)

**Infrastructure**:
- Frontend: Vercel
- Backend: Railway or Fly.io
- Storage: Supabase Storage (PDF reports)
- Monitoring: Sentry
- Analytics: PostHog

**Cost**: ~$100/month for 1,000 analyses

---

## API Design

### Core Endpoints

```python
# POST /api/v1/analyze
# Upload and analyze mutation data
{
  "file": "mutations.csv",
  "options": {
    "driver_genes": true,
    "pathway_enrichment": true,
    "tmb_calculation": true,
    "actionable_mutations": true
  }
}

# Response
{
  "analysis_id": "uuid",
  "status": "processing",
  "estimated_time": 120,  # seconds
  "cost_credits": 1
}

# GET /api/v1/analysis/{analysis_id}
# Check analysis status
{
  "analysis_id": "uuid",
  "status": "completed",
  "progress": 100,
  "results_url": "/api/v1/analysis/{uuid}/results",
  "report_url": "/api/v1/analysis/{uuid}/report.pdf"
}

# GET /api/v1/analysis/{analysis_id}/results
# Get analysis results (JSON)
{
  "driver_genes": [
    {"gene": "TP53", "mutations": 45, "frequency": 0.23},
    {"gene": "KRAS", "mutations": 32, "frequency": 0.16}
  ],
  "pathways": {
    "TP53_Pathway": {"genes": ["TP53", "MDM2"], "p_value": 0.001},
    "RAS_RAF_MEK_ERK": {"genes": ["KRAS", "BRAF"], "p_value": 0.005}
  },
  "tmb": {
    "mutations_per_mb": 12.5,
    "immunotherapy_eligible": true
  },
  "actionable_mutations": [
    {
      "gene": "BRAF",
      "mutation": "V600E",
      "drugs": ["Vemurafenib", "Dabrafenib"],
      "fda_approved": true
    }
  ]
}
```

### Authentication

```python
# POST /api/v1/auth/register
{
  "email": "researcher@university.edu",
  "password": "secure_password",
  "organization": "Stanford Cancer Center"
}

# POST /api/v1/auth/login
{
  "email": "researcher@university.edu",
  "password": "secure_password"
}

# Response (JWT token)
{
  "access_token": "eyJ...",
  "refresh_token": "eyJ...",
  "user": {
    "id": "uuid",
    "email": "researcher@university.edu",
    "plan": "pro",
    "credits_remaining": 150
  }
}
```

---

## Pricing Strategy

### Subscription Tiers

**Free Tier** (Lead Generation)
- 10 samples/month
- Basic analysis only
- PDF reports
- Email support
- **Price**: $0

**Starter** (Small Labs)
- 50 samples/month ($2/sample)
- Full analysis suite
- Priority processing
- PDF + Excel reports
- Email support
- **Price**: $99/month

**Pro** (Medium Labs)
- 200 samples/month ($1.50/sample)
- Everything in Starter
- API access
- Custom branding on reports
- Slack/Email support
- **Price**: $299/month

**Enterprise** (Large Labs/Pharma)
- 1,000 samples/month ($1/sample)
- Everything in Pro
- Dedicated account manager
- Custom integrations
- On-premise deployment option
- Priority support (24/7)
- **Price**: $999/month

**Pay-as-you-go**
- $5/sample
- No commitment
- Good for occasional users

### Revenue Model

**Year 1 Projections (Conservative)**:
```
Free tier:     1,000 users × $0 = $0 (lead generation)
Starter:       100 users × $99 = $9,900/month
Pro:           30 users × $299 = $8,970/month
Enterprise:    20 users × $999 = $19,980/month
Pay-as-go:     500 samples × $5 = $2,500/month

Total MRR: $41,350
Total ARR: $496,200
```

**Year 2 Projections (Growth)**:
```
Free tier:     5,000 users × $0 = $0
Starter:       300 users × $99 = $29,700/month
Pro:           150 users × $299 = $44,850/month
Enterprise:    50 users × $999 = $49,950/month
Pay-as-go:     1,000 samples × $5 = $5,000/month

Total MRR: $129,500
Total ARR: $1,554,000
```

### Unit Economics

**Cost per Analysis**:
- OpenRouter API (DeepSeek): $0.02
- Server costs: $0.01
- Storage (PDF): $0.001
- **Total COGS**: $0.031

**Gross Margin**:
- Starter tier: ($2 - $0.03) / $2 = **98.5%**
- Pro tier: ($1.50 - $0.03) / $1.50 = **98.0%**
- Enterprise: ($1 - $0.03) / $1 = **97.0%**

**Customer Acquisition Cost (CAC)**:
- Content marketing: $50/customer
- Paid ads: $100/customer
- Target CAC: $75/customer

**Lifetime Value (LTV)**:
- Avg subscription: $200/month
- Avg retention: 24 months
- LTV: $200 × 24 = $4,800

**LTV/CAC Ratio**: $4,800 / $75 = **64:1** (Excellent!)

---

## Go-to-Market Strategy

### Phase 1: MVP Launch (Month 1-3)

**Objectives**:
- Launch beta version
- Get 100 free tier users
- Convert 10 paying customers
- Validate product-market fit

**Tactics**:
1. **Product Hunt Launch**
   - Submit to Product Hunt
   - Offer lifetime deal for first 100 users ($299 one-time)
   - Target: 500 upvotes, 1,000 visitors

2. **Content Marketing**
   - Blog: "How to Analyze Cancer Mutations for $1 Instead of $1,000"
   - Blog: "Top 10 Driver Genes in Lung Cancer (with Free Analysis)"
   - Guest post on r/bioinformatics, r/genomics

3. **Academic Outreach**
   - Email 500 cancer research PIs
   - Offer free analysis for first published paper
   - Case study: "Stanford Lab Saves $50K/year with CancerGenomics.AI"

4. **Social Media**
   - Twitter: Daily tips on cancer genomics
   - LinkedIn: Case studies and tutorials
   - YouTube: "How to analyze TCGA data in 5 minutes"

### Phase 2: Growth (Month 4-9)

**Objectives**:
- 1,000 free tier users
- 100 paying customers
- $30K MRR

**Tactics**:
1. **Integration Partnerships**
   - cBioPortal integration (direct upload from portal)
   - TCGA data portal integration
   - Galaxy workflow integration

2. **Referral Program**
   - Give $50 credit for each referral
   - Referrer gets 1 month free

3. **Webinars**
   - Monthly webinar: "Cancer Genomics Analysis 101"
   - Partner with genomics companies for co-marketing

4. **Conference Presence**
   - AACR, ASCO, ASHG conferences
   - Booth + live demos
   - Sponsor academic talks

### Phase 3: Scale (Month 10-24)

**Objectives**:
- 5,000 free tier users
- 500 paying customers
- $125K MRR

**Tactics**:
1. **Enterprise Sales**
   - Hire 2 enterprise sales reps
   - Target pharma/biotech companies
   - Custom contracts for high-volume users

2. **API Marketplace**
   - Launch on RapidAPI
   - Offer API-only tier ($0.10/analysis)
   - Target software developers building genomics tools

3. **White-Label**
   - Offer white-label solution to biotech companies
   - $5K/month + rev share

4. **International Expansion**
   - Multilingual support (Chinese, Japanese, German)
   - Local partnerships in Europe, Asia
   - Compliance: GDPR, HIPAA

---

## Development Roadmap

### MVP (Weeks 1-4)

**Week 1**: Backend API
- FastAPI setup
- GenomicsAnalysisAgent integration
- OpenRouter integration (DeepSeek)
- Database schema (PostgreSQL)
- Authentication (JWT)

**Week 2**: Frontend
- Next.js app setup
- File upload component
- Dashboard UI
- Results viewer
- Stripe integration

**Week 3**: Analysis Pipeline
- CSV/VCF parser
- Driver gene identification
- Pathway enrichment
- TMB calculation
- PDF report generation

**Week 4**: Launch Prep
- Landing page
- Documentation
- Onboarding flow
- Beta tester recruitment
- Product Hunt submission

### Post-MVP Enhancements

**Month 2-3**:
- API access for Pro users
- Batch upload (multiple files)
- Custom pathway databases
- Email notifications
- Improved visualizations

**Month 4-6**:
- Clinical trial matching
- Drug-gene interaction database
- Survival analysis integration (SurvivalAnalysisAgent)
- Team collaboration features
- Version control for analyses

**Month 7-12**:
- White-label solution
- On-premise deployment
- Mobile app (iOS/Android)
- Advanced ML models (mutation impact prediction)
- Integration marketplace

---

## Financial Projections

### Startup Costs

**One-time**:
- Legal (incorporation, terms): $2,000
- Design (logo, branding): $1,500
- Initial marketing: $5,000
- **Total**: $8,500

**Monthly (Fixed)**:
- Infrastructure (Vercel + Railway + Supabase): $100
- Software subscriptions: $200
- Marketing: $2,000
- Founder salary (Year 1): $0 (bootstrapped)
- **Total**: $2,300/month

### Breakeven Analysis

**Monthly costs**: $2,300
**COGS per customer** (Starter): $99 × 0.015 = $1.50
**Net revenue per customer**: $99 - $1.50 = $97.50

**Breakeven**: 24 customers ($2,300 / $97.50)

**Timeline to breakeven**: 2-3 months (with good marketing)

### 3-Year Revenue Projection

**Year 1**:
- Customers: 150 (avg)
- MRR: $30,000
- ARR: $360,000
- Expenses: $50,000
- **Profit**: $310,000

**Year 2**:
- Customers: 600 (avg)
- MRR: $125,000
- ARR: $1,500,000
- Expenses: $200,000 (1 FTE hire)
- **Profit**: $1,300,000

**Year 3**:
- Customers: 2,000 (avg)
- MRR: $420,000
- ARR: $5,000,000
- Expenses: $750,000 (5 FTE team)
- **Profit**: $4,250,000

---

## Risk Analysis

### Technical Risks

**1. AI Model Quality**
- **Risk**: Ultra-budget models produce inaccurate results
- **Mitigation**:
  - Validate against TCGA gold standard datasets
  - Use Claude 3.5 Sonnet for quality tier
  - Human review for enterprise customers

**2. Scalability**
- **Risk**: System can't handle high volume
- **Mitigation**:
  - Async processing with Celery
  - Horizontal scaling on Railway
  - Caching with Redis

**3. OpenRouter Dependency**
- **Risk**: OpenRouter API downtime or price changes
- **Mitigation**:
  - Multi-provider fallback (direct Anthropic, OpenAI)
  - Contract negotiation for enterprise volume
  - Self-hosted model option for critical workloads

### Business Risks

**1. Regulatory Compliance**
- **Risk**: HIPAA/GDPR violations
- **Mitigation**:
  - Legal review of data handling
  - Encrypt data at rest and in transit
  - Clear terms of service (research use only)
  - BAA for enterprise customers

**2. Competition**
- **Risk**: DNAnexus or Tempus launches similar product
- **Mitigation**:
  - First-mover advantage (launch fast)
  - Focus on ease of use (vs complexity)
  - Build moat with integrations and community

**3. Market Adoption**
- **Risk**: Researchers don't trust AI-generated results
- **Mitigation**:
  - Transparency: show generated code
  - Validation: compare to published results
  - Education: webinars on AI in genomics
  - Endorsements: partnerships with academic labs

---

## Success Metrics

### Product Metrics

**Activation**:
- % of signups who upload first file: Target 70%
- Time to first analysis: Target <5 min

**Engagement**:
- Avg analyses per user/month: Target 15
- DAU/MAU ratio: Target 30%
- Report download rate: Target 90%

**Retention**:
- Month 1 retention: Target 70%
- Month 6 retention: Target 50%
- Annual retention: Target 80%

### Business Metrics

**Growth**:
- MoM user growth: Target 20%
- MoM revenue growth: Target 25%
- Free-to-paid conversion: Target 10%

**Economics**:
- CAC: Target <$100
- LTV: Target >$3,000
- LTV/CAC: Target >30:1
- Gross margin: Target >95%

### Quality Metrics

**Technical**:
- API uptime: Target 99.9%
- Analysis completion rate: Target 98%
- Accuracy vs TCGA gold standard: Target >95%

**Customer Satisfaction**:
- NPS score: Target >50
- Support response time: Target <4 hours
- Customer review rating: Target 4.5+/5

---

## Exit Strategy

### Acquisition Targets

**Tier 1** ($50M-100M acquisition):
- Illumina (genomics sequencing)
- Tempus (cancer data platform)
- Foundation Medicine (Roche subsidiary)

**Tier 2** ($20M-50M acquisition):
- DNAnexus (cloud genomics)
- SOPHiA GENETICS (AI genomics)
- QIAGEN (bioinformatics)

### Timeline

- **Year 1-2**: Build product, prove model, reach $1M ARR
- **Year 3**: Scale to $5M ARR, raise Series A ($3M-5M)
- **Year 4-5**: Reach $20M ARR, entertain acquisition offers
- **Exit**: $50M-100M acquisition (10-20x ARR multiple)

### Alternative: IPO Path

If acquisition doesn't materialize:
- Continue scaling to $50M+ ARR
- Expand to other disease areas (rare diseases, cardiology)
- Vertical integration (sequencing → analysis → clinical decision support)
- IPO at $200M+ valuation

---

## Conclusion

**CancerGenomics.AI** represents a massive opportunity to democratize cancer genomics analysis. By leveraging ultra-budget AI models and the existing ai-data-science-team infrastructure, we can launch in **4 weeks** with minimal capital investment.

**Key advantages**:
- ✅ 98% gross margins (vs 60% for traditional SaaS)
- ✅ Tech already built (ai-data-science-team library)
- ✅ Clear market pain point ($80K bioinformatician vs $99/month)
- ✅ Fast validation (launch in 1 month)
- ✅ Massive TAM ($3B cancer genomics services)

**Next steps**:
1. **Week 1**: Build MVP backend (FastAPI + GenomicsAnalysisAgent)
2. **Week 2**: Build MVP frontend (Next.js + Stripe)
3. **Week 3**: Beta testing with 10 research labs
4. **Week 4**: Product Hunt launch + initial marketing

**Let's build this!** 🚀
